Linkedin Twitter
Contact

Careers

Joining the Synaffix Team

“At Synaffix, our core values include scientific excellence, transparency and embracing the collective genius across the entire team.”
– Peter van de Sande, CEO

We are passionate about delivering cutting-edge enabling technologies and best-in-class targeted cancer therapeutics.

In joining Synaffix, you join a fast-paced, highly collaborative team where innovation is at the center of everything we do. 

Our efforts are aimed at improving the health of patients globally and to realize our ambition – Connect to Cure™.

If you are interested in becoming part of our exciting and dynamic team, please get in touch with us at .

Available Positions

Currently there are no available positions listed.

Protein Conjugates

Bring your own and/or choose from the following categories. 

 

Just like our ADC technology, we can easily attach peptide and protein-based payloads to your antibody.

 

Early preclinical data available on request.

Bring Your Own

scFv / Fab
Cytokine

Immune Cell Recruiters

Anti-CD3

T cell recruitment
IL-15

NK cell recruitment

IL-15 Receptor Fusion

NK cell recruitment

HydraSpace® Polar Spacer

Forming an integral part of every toxSYN® linker-payload, HydraSpace® bears a negative charge at physiological pH and improves:
  1. Therapeutic efficacy
  2. Tolerability
  3. PK
  4. Manufacturability
Key publication about HydraSpace
HydraSpace®
GlycoConnect® design easily matches payload potency with the most appropriate drug-antibody ratio (DAR).

Key publications about GlycoConnect®

GlycoConnect® ADCs
Metal-Free Click Conjugation
Enzymatic ADCs (Review)
DAR1 Drug Antibody Ratio 1:1
DAR1
Drug Antibody Ratio 1:1
DAR2 Drug Antibody Ratio 2:1
DAR2
Drug Antibody Ratio 2:1
DAR4 Drug Antibody Ratio 4:1
DAR4
Drug Antibody Ratio 4:1

toxSYN® Linker-Payloads

Choose from the following linker-payloads, attach to your antibody under a technology evaluation and go straight into ADC product development following positive POC.
DAR1 Drug Antibody Ratio 1:1
DAR1
Drug Antibody Ratio 1:1
DAR4 Drug Antibody Ratio 4:1
DAR4
Drug Antibody Ratio 4:1
DAR2 Drug Antibody Ratio 2:1
DAR2
Drug Antibody Ratio 2:1
toxSYN®
Linker-Payload		 Mode-of-Action Payload
(Active Catabolite)
1. SYNtecan E™*Topoisomerase 1 inhibitor Camptothecin-based
2. SYNeamicin D™*DNA
damaging agent		 Calicheamicin-based
3. SYNeamicin G™*
4. SYN-PNU™*Nemorubicin-based
5. SYNstatin E™Microtubule
inhibitors		 Auristatin-based
6. SYNstatin F™
7. SYNtansine™ Maytansine-based
* Patent protection filed by Synaffix, beyond the claims of GlycoConnect® and HydraSpace® ** N-6-aminohexanoyl-maytansine (Ahx-maytansine)